New cancer drug KK2260 enters first human tests
NCT ID NCT06248411
First seen Feb 22, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This early-phase trial is testing a new drug called KK2260 in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test different dosing schedules in patients with esophageal or head and neck cancers. About 189 participants will be enrolled to evaluate safety, side effects, and early signs of tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aichi Cancer Center Hospital
RECRUITINGNagoya, Aichi-ken, 464-8681, Japan
-
Hiroshima University Hospital
RECRUITINGHiroshima, Hiroshima, 734-8551, Japan
-
Kanagawa Cancer Center
RECRUITINGYokohama, Kanagawa, 241-8515, Japan
-
Kobe University Hospital
RECRUITINGKobe, Hyōgo, 650-0017, Japan
-
Kumamoto University Hospital
RECRUITINGKumamoto, Kumamoto, 860-8556, Japan
-
Kyushu Cancer Center
RECRUITINGFukuoka, 811-1347, Japan
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Chiba, 277-8577, Japan
-
Osaka International Cancer Institute
RECRUITINGOsaka, 540-0008, Japan
-
Saitama Cancer Center
RECRUITINGShinden, Saitama, 362-0806, Japan
-
Shikoku Cancer Center
RECRUITINGMatsuyama, Ehime, 791-0280, Japan
-
Shizuoka Cancer Center
RECRUITINGNagaizumi-cho, Shizuoka, 411-8777, Japan
-
The Cancer Institute Hospital of JFCR
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
-
Tohoku University Hospital
RECRUITINGSendai, Miyagi, 980-8574, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KK2260 (an experimental drug given intravenously)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors, including esophageal and head and neck cancers.
What could go wrong
This is a very early, first-in-human study with a small number of participants. The drug may not work or could cause unexpected side effects. It will take years before any potential treatment is available.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.